ジェノタイピングアッセイの世界市場予測（～2023年）...市場調査レポートについてご紹介

TABLE OF CONTENTS

1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 MARKET SCOPE 23
1.3.1 MARKETS COVERED 23
1.3.2 MARKET SEGMENTATION, BY REGION 24
1.3.3 YEARS CONSIDERED FOR THE STUDY 24
1.4 CURRENCY 25
1.5 LIMITATIONS 25
1.6 STAKEHOLDERS 25
2 RESEARCH METHODOLOGY 26
2.1 RESEARCH DATA 26
2.1.1 SECONDARY DATA 27
2.1.1.1 Key data from secondary sources 28
2.1.2 PRIMARY DATA 28
2.1.2.1 Key data from primary sources 30
2.1.2.2 Key industry insights 31
2.2 MARKET SIZE ESTIMATION 32
2.2.1 BOTTOM-UP APPROACH 33
2.2.2 TOP-DOWN APPROACH 33
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 34
2.4 ASSUMPTIONS FOR THE STUDY 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 44
4.1 GENOTYPING MARKET OVERVIEW 44
4.2 ASIA PACIFIC: GENOTYPING MARKET, BY PRODUCT & SERVICE, BY COUNTRY, 2017 45
4.3 GEOGRAPHIC SNAPSHOT OF THE GENOTYPING MARKET 46
4.4 GEOGRAPHIC MIX: GENOTYPING MARKET 47
4.5 GENOTYPING MARKET: DEVELOPING VS. DEVELOPED MARKETS 47
 
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 48
5.3 MARKET DRIVERS 49
5.3.1 TECHNOLOGICAL ADVANCEMENTS AND DECREASING PRICES OF DNA SEQUENCING 49
5.3.2 INCREASING INCIDENCE OF GENETIC DISEASES AND RISING AWARENESS ON PERSONALIZED MEDICINE 50
5.3.3 GROWING IMPORTANCE OF GENOTYPING IN DRUG DEVELOPMENT 51
5.3.4 INCREASING DEMAND FOR BIOINFORMATICS SOLUTIONS IN DATA ANALYSIS 51
5.4 MARKET RESTRAINTS 52
5.4.1 HIGH COST OF EQUIPMENT USED IN GENOTYPING 52
5.5 MARKET OPPORTUNITIES 52
5.5.1 GROWING IMPORTANCE OF SEQUENCING PROJECTS 52
5.5.2 INCREASING APPLICATION AREAS OF GENOTYPING 53
5.5.3 INCREASING DEMAND FOR GENOME ANALYSIS IN PLANT AND ANIMAL LIVESTOCK 53
5.6 MARKET CHALLENGES 54
5.6.1 DATA MANAGEMENT IN GENOTYPING RESEARCH 54
5.6.2 DEARTH OF TRAINED RESOURCES 54
6 INDUSTRY INSIGHTS 55
6.1 INDUSTRY TRENDS 55
6.1.1 INCREASING DEMAND FOR GENOTYPING & SEQUENCING SERVICES 55
6.1.2 INCREASING COLLABORATIONS 55
6.1.3 INCREASING AWARENESS 56
6.2 REGULATORY ANALYSIS 57
6.2.1 US 57
6.2.2 EUROPE 58
6.2.3 JAPAN 58
6.2.4 CHINA 59
6.2.5 INDIA 60
6.3 STRATEGIC BENCHMARKING 61
6.3.1 GENOTYPING MARKET: PRODUCT PORTFOLIO ANALYSIS (INSTRUMENTS & KITS) 61
6.3.2 GENOTYPING MARKET: PRODUCT PORTFOLIO ANALYSIS (BIOINFORMATICS) 62
 
7 GENOTYPING MARKET, BY PRODUCT & SERVICE 63
7.1 INTRODUCTION 64
7.2 REAGENTS & KITS 65
7.2.1 REAGENTS & KITS ACCOUNTED FOR THE LARGEST SHARE OF THE GENOTYPING MARKET IN 2017 65
7.3 GENOTYPING SERVICES 66
7.3.1 INCREASING DEMAND FOR SEQUENCING AND GENOTYPING SERVICES FROM HOSPITALS, SMALL- AND MEDIUM-SIZED RESEARCH CENTERS, AND PHARMACEUTICAL COMPANIES TO DRIVE THE GROWTH OF THIS SEGMENT 66
7.4 INSTRUMENTS 67
7.4.1 SEQUENCERS & AMPLIFIERS 69
7.4.1.1 Sequencers & amplifiers segment to register the highest growth rate in the genotyping instruments market during the forecast period 69
7.4.2 ANALYZERS 70
7.4.2.1 Growing automation and advancements in analyzers with high-throughput capacities are the major factors driving market growth 70
7.5 BIOINFORMATICS 71
7.5.1 SOFTWARE 73
7.5.1.1 Software segment accounted for the largest share of the genotyping bioinformatics market in 2017 73
7.5.2 SERVICES 74
7.5.2.1 Shortage of skilled bioinformatics professionals and the growing applications of bioinformatics in various industries are the major factors driving the growth of this segment 74
8 GENOTYPING MARKET, BY TECHNOLOGY 76
8.1 INTRODUCTION 77
8.2 POLYMERASE CHAIN REACTION 78
8.2.1 REAL-TIME PCR 80
8.2.1.1 Real-time PCR dominated the PCR market in 2017, primarily due to the growing adoption of these instruments among researchers and healthcare professionals 80
8.2.2 DIGITAL PCR 83
8.2.2.1 The high cost of dPCR instruments to restrain the growth of this market 83
8.3 MICROARRAYS 85
8.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE AND CONTINUOUS LAUNCH OF CUSTOM ARRAYS BY LEADING PLAYERS TO DRIVE MARKET GROWTH 85
8.4 SEQUENCING 88
8.4.1 NEXT-GENERATION SEQUENCING 90
8.4.1.1 NGS to witness the highest growth rate in the sequencing market during the forecast period 90
 
8.4.2 PYROSEQUENCING 92
8.4.2.1 Growing demand for pyrosequencing by pharmaceutical and biotechnology companies to drive the adoption of this technology segment 92
8.4.3 SANGER SEQUENCING 94
8.4.3.1 Increasing use of this technology in small-scale experiments is the major factor driving market growth 94
8.5 CAPILLARY ELECTROPHORESIS 96
8.5.1 AMPLIFIED FRAGMENT LENGTH POLYMORPHISM 98
8.5.1.1 AFLP technique to witness the highest growth rate in the capillary electrophoresis market during the forecast period 98
8.5.2 RESTRICTION FRAGMENT LENGTH POLYMORPHISM 99
8.5.2.1 Increasing demand for RFLP from forensics, agricultural institutions, and pharmaceutical and biotechnology companies–major factor driving market growth 99
8.5.3 SINGLE-STRAND CONFORMATION POLYMORPHISM 101
8.5.3.1 Increasing applications of SSCP in virology are expected to play a key role in the growth of the SSCP market 101
8.6 MATRIX-ASSISTED LASER DESORPTION/IONIZATION-TIME OF FLIGHT (MALDI-TOF) MASS SPECTROMETRY 102
8.6.1 INCREASING APPLICATIONS OF THIS TECHNIQUE IN CLINICAL DIAGNOSTICS AND PHARMACOGENOMICS TO DRIVE MARKET GROWTH 102
8.7 OTHER TECHNOLOGIES 104
9 GENOTYPING MARKET, BY APPLICATION 106
9.1 INTRODUCTION 107
9.2 PHARMACOGENOMICS 108
9.2.1 PHARMACOGENOMICS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE GENOTYPING MARKET IN 2017 108
9.3 DIAGNOSTICS & PERSONALIZED MEDICINE 110
9.3.1 TECHNOLOGICAL ADVANCEMENTS AND INCREASING POTENTIAL OF DEVELOPING DIAGNOSTICS TESTS THROUGH RAPID GENOTYPING TECHNIQUES ARE THE KEY FACTORS DRIVING THE GROWTH OF THIS APPLICATION SEGMENT 110
9.4 ANIMAL GENETICS 111
9.4.1 LOWER ADOPTION OF GENOTYPING TECHNOLOGIES IN ANIMAL BREEDING PROGRAMS IN DEVELOPING COUNTRIES TO RESTRAIN THE GROWTH OF THIS SEGMENT 111
9.5 AGRICULTURAL BIOTECHNOLOGY 113
9.5.1 INCREASING NUMBER OF RESEARCH LABORATORIES AND GREENHOUSES USING PLANT GENOTYPING AND CONTINUOUS PRODUCT INNOVATIONS AND NEW PRODUCT LAUNCHES ARE DRIVING THE GROWTH OF THE AGRICULTURAL BIOTECHNOLOGY SEGMENT 113
9.6 OTHER APPLICATIONS 114
 
10 GENOTYPING MARKET, BY END USER 116
10.1 INTRODUCTION 117
10.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 118
10.2.1 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 118
10.3 DIAGNOSTIC & RESEARCH LABORATORIES 119
10.3.1 GROWING PREFERENCE FOR PERSONALIZED MEDICINE AND INCREASING RESEARCH FOCUSED ON PERSONALIZED DIAGNOSIS ARE THE KEY FACTORS DRIVING MARKET GROWTH 119
10.4 ACADEMIC INSTITUTES 121
10.4.1 INCREASING RESEARCH ACTIVITIES FOR DRUG DISCOVERY AND RISING INDUSTRY-ACADEMIA COLLABORATIONS FOR DRUG DEVELOPMENT ARE THE KEY FACTORS DRIVING MARKET GROWTH 121
10.5 OTHER END USERS 122
11 GENOTYPING MARKET, BY REGION 124
11.1 INTRODUCTION 125
11.2 NORTH AMERICA 126
11.2.1 US 131
11.2.1.1 US dominated the North American genotyping market in 2018; this trend to continue during the forecast period 131
11.2.2 CANADA 135
11.2.2.1 Increasing incidence of genetic diseases & the availability of a wide range of genotyping products to drive market growth in Canada 135
11.3 EUROPE 139
11.3.1 GERMANY 144
11.3.1.1 Germany accounted for the largest share of the European genotyping market in 2017 144
11.3.2 FRANCE 148
11.3.2.1 Increasing incidence of genetic disorders & growing public-private investments are driving the growth of the genotyping market in France 148
11.3.3 UK 151
11.3.3.1 UK to witness the highest growth in the European genotyping market during the forecast period 151
11.3.4 ITALY 155
11.3.4.1 Presence of a well-developed healthcare system and rapid growth in the geriatric population are key factors driving market growth in Italy 155
11.3.5 SPAIN 159
11.3.5.1 The lingering effect of economic downturns will continue to affect healthcare in Spain 159
11.3.6 REST OF EUROPE 163
11.4 ASIA PACIFIC 166
11.4.1 CHINA 171
11.4.1.1 Infrastructural improvements in China’s healthcare system have boosted treatment rates and care delivery 171
11.4.2 JAPAN 175
11.4.2.1 Strong base of pharmaceutical activity will contribute to the use of genotyping 175
11.4.3 INDIA 179
11.4.3.1 Growth of the pharmaceutical industry has highlighted the need for better infrastructure in India 179
11.4.4 REST OF APAC 183
11.5 LATIN AMERICA 187
11.6 MIDDLE EAST AND AFRICA 191
12 COMPETITIVE LANDSCAPE 195
12.1 OVERVIEW 195
12.2 PRODUCT PORTFOLIO MATRIX 196
12.3 MARKET SHARE ANALYSIS 197
12.4 COMPETITIVE SITUATIONS AND TRENDS 198
12.4.1 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 200
12.4.2 ACQUISITIONS 201
12.4.3 EXPANSIONS 202
13 COMPANY PROFILES 204
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
13.1 ILLUMINA, INC. 204
13.2 THERMO FISHER SCIENTIFIC, INC. 210
13.3 ROCHE DIAGNOSTICS LIMITED 218
13.4 QIAGEN N.V. 223
13.5 DANAHER CORPORATION 230
13.6 AGILENT TECHNOLOGIES, INC. 233
13.7 FLUIDIGM CORPORATION 241
13.8 GE HEALTHCARE 244
13.9 GENEWIZ, INC. 248
13.10 INTEGRATED DNA TECHNOLOGIES, INC. (A SUBSIDIARY OF DANAHER CORPORATION) 251
13.11 PERKINELMER, INC. 255
13.12 BIO-RAD LABORATORIES, INC. 260
13.13 EUROFINS SCIENTIFIC 263
13.14 PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 267

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
 
14 APPENDIX 271
14.1 INSIGHTS OF INDUSTRY EXPERTS 271
14.2 DISCUSSION GUIDE 272
14.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 277
14.4 AVAILABLE CUSTOMIZATIONS 279
14.5 RELATED REPORT 279
14.6 AUTHOR DETAILS 280